Impact of Severe Obstructive Sleep Apnea-Hypopnea Syndrome on Auditory-Cognitive Processing
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jun 17, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how severe obstructive sleep apnea-hypopnea syndrome (OSAHS), a condition where breathing stops and starts during sleep, might affect the brain’s ability to process sounds and pay attention during the day. Researchers want to find out if people with severe OSAHS have changes in how their brain detects sounds automatically, if they have trouble focusing on important sounds, and if special brainwave tests (called EEGs) can spot early hearing-related thinking problems before any symptoms show up.
The study will include adults aged 20 to 60 who have normal hearing and good thinking skills. One group will have 50 people diagnosed with severe OSAHS through sleep tests, and the other group will have 50 healthy adults without sleep problems. Participants will take hearing and thinking tests, have a one-night sleep study, and wear an EEG cap for about 1.5 to 2 hours while listening to different sounds. During this time, they will sometimes relax and just listen, and other times press a button when they hear rare sounds. Participants will be paid for their time. This study is not yet recruiting but aims to help us better understand how severe sleep apnea may affect brain and hearing health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- All Participants:
- • Aged 20-60 years
- • Normal hearing (PTA ≤25 dB HL at 0.5,1,2,4 kHz; Type A tympanogram)
- • MoCA score ≥26
- • Willing to complete EEG testing
- OSAHS Group Additional:
- • - PSG-confirmed severe OSAHS (AHI \>30 events/hour)
- Control Group Additional:
- • Self-reported absence of snoring/sleep disorders
- • No prior OSAHS diagnosis
- Exclusion Criteria:
- All Participants:
- * History of:
- • Schizophrenia, epilepsy, Parkinson's, TBI, or language disorders
- • Middle/inner ear diseases (otitis media, acoustic neuroma, etc.)
- • Cognitive impairment or depression/anxiety disorders
- • Chronic steroid use
- • Systemic inflammatory diseases or malignancies
- • Pregnancy or suspected pregnancy (self-reported)
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported